title: Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience.
abstract: Brain tumors are a major cause of cancer-related mortality in children. Overexpression of epidermal growth factor receptor (EGFR) is detected in pediatric brain tumors and receptor density appears to increase with tumor grading. Nimotuzumab is an IgG1 antibody that targets EGFR. Twenty-three children with high-grade glioma (HGG) were enrolled in an expanded access program in which nimotuzumab was administered alone or with radio-chemotherapy. The mean number of doses was 39. Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.
authors.affiliation: Oncohematology, Juan Manuel Márquez Pediatric Hospital, Havana, Cuba.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Cabanas
authors.forename: Giselle
authors.initials: G
authors.lastname: Saurez
authors.forename: Martha
authors.initials: M
authors.lastname: Rios
authors.forename: Jose
authors.initials: J
authors.lastname: Alert
authors.forename: Adnolys
authors.initials: A
authors.lastname: Reyes
authors.forename: Jose
authors.initials: J
authors.lastname: Valdes
authors.forename: Maria C
authors.initials: MC
authors.lastname: Gonzalez
authors.forename: Jorge L
authors.initials: JL
authors.lastname: Pedrayes
authors.forename: Melba
authors.initials: M
authors.lastname: Avila
authors.forename: Raiza
authors.initials: R
authors.lastname: Herrera
authors.forename: Mariela
authors.initials: M
authors.lastname: Infante
authors.forename: Ernesto
authors.initials: E
authors.lastname: Echevarria
authors.forename: Myrna
authors.initials: M
authors.lastname: Moreno
authors.forename: Patricia Lorenzo
authors.initials: PL
authors.lastname: Luaces
authors.forename: Tania Crombet
authors.initials: TC
authors.lastname: Ramos
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D001254:Astrocytoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004358:Drug Therapy; D066246:ErbB Receptors / Q000276:immunology; D005260:Female; D005910:Glioma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D011878:Radiotherapy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C501466:nimotuzumab; D066246:ErbB Receptors
keywords: High grade glioma; anaplastic astrocytoma; children glioma; glioblastoma multiforme; monoclonal antibody; nimotuzumab